Temporal and geographic variation in the systemic treatment of advanced prostate cancer

BACKGROUND: Several systemic treatments have been shown to increase survival for patients with metastatic castration-resistant prostate cancer. This study sought to characterize variation in use of the six “focus drugs” (docetaxel, abiraterone, enzalutamide, sipuleucel-T, radium-223, and cabazitaxel...

Descripción completa

Detalles Bibliográficos
Autores principales: Caram, Megan E. V., Estes, Jason P., Griggs, Jennifer J., Lin, Paul, Mukherjee, Bhramar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840834/
https://www.ncbi.nlm.nih.gov/pubmed/29510667
http://dx.doi.org/10.1186/s12885-018-4166-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840834/
https://www.ncbi.nlm.nih.gov/pubmed/29510667
http://dx.doi.org/10.1186/s12885-018-4166-3

Ejemplares similares